Monika Peeters

5.5k total citations · 1 hit paper
64 papers, 4.2k citations indexed

About

Monika Peeters is a scholar working on Infectious Diseases, Hepatology and Virology. According to data from OpenAlex, Monika Peeters has authored 64 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Infectious Diseases, 28 papers in Hepatology and 27 papers in Virology. Recurrent topics in Monika Peeters's work include HIV/AIDS drug development and treatment (44 papers), Hepatitis C virus research (28 papers) and HIV Research and Treatment (27 papers). Monika Peeters is often cited by papers focused on HIV/AIDS drug development and treatment (44 papers), Hepatitis C virus research (28 papers) and HIV Research and Treatment (27 papers). Monika Peeters collaborates with scholars based in Belgium, United States and United Kingdom. Monika Peeters's co-authors include Brian Woodfall, Goedele De Smedt, Oliver Lenz, Rekha Sinha, Jane Scott, Maria Beumont‐Mauviel, Johan Vingerhoets, Sivi Ouwerkerk‐Mahadevan, Ronald Kalmeijer and Guy De La Rosa and has published in prestigious journals such as The Lancet, Gastroenterology and Hepatology.

In The Last Decade

Monika Peeters

64 papers receiving 4.0k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Ira M. Jacobson, Gregory J. Dore et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Monika Peeters Belgium	33	2.5k	2.3k	2.3k	1.5k	253	64	4.2k
Pablo Labarga Spain	36	2.0k 0.8×	2.2k 0.9×	2.1k 0.9×	849 0.6×	160 0.6×	137	3.8k
Stefan Mauss Germany	40	1.8k 0.7×	4.1k 1.8×	4.3k 1.9×	683 0.5×	123 0.5×	191	5.6k
Eugenia Vispo Spain	31	1.1k 0.5×	1.8k 0.7×	1.9k 0.8×	489 0.3×	173 0.7×	104	2.9k
L Molé United States	26	1.3k 0.5×	2.3k 1.0×	1.7k 0.7×	526 0.4×	120 0.5×	57	3.3k
Diana M. Brainard United States	50	2.6k 1.1×	5.3k 2.3×	5.7k 2.5×	911 0.6×	318 1.3×	189	7.6k
Hartwig Klinker Germany	31	1.1k 0.4×	1.6k 0.7×	1.3k 0.6×	472 0.3×	279 1.1×	157	2.9k
Marina Núñez Spain	33	1.5k 0.6×	2.3k 1.0×	2.3k 1.0×	490 0.3×	85 0.3×	104	3.4k
Peter Ruane United States	32	3.4k 1.4×	1.7k 0.7×	940 0.4×	2.2k 1.5×	499 2.0×	78	4.7k
Arthur Y. Kim United States	38	1.2k 0.5×	2.7k 1.2×	3.3k 1.4×	658 0.4×	390 1.5×	121	4.9k
Marc van der Valk Netherlands	39	2.6k 1.0×	1.6k 0.7×	1.0k 0.4×	1.9k 1.3×	368 1.5×	212	4.6k

Countries citing papers authored by Monika Peeters

Since Specialization

Citations

This map shows the geographic impact of Monika Peeters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monika Peeters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monika Peeters more than expected).

Fields of papers citing papers by Monika Peeters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monika Peeters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monika Peeters. The network helps show where Monika Peeters may publish in the future.

Co-authorship network of co-authors of Monika Peeters

This figure shows the co-authorship network connecting the top 25 collaborators of Monika Peeters. A scholar is included among the top collaborators of Monika Peeters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monika Peeters. Monika Peeters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. PMC. 5 indexed citations

Ouwerkerk‐Mahadevan, Sivi, Jan Snoeys, Monika Peeters, Maria Beumont‐Mauviel, & Alexandru Simion. (2015). Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clinical Pharmacokinetics. 55(2). 197–208. 63 indexed citations

Lawitz, Eric, Edwin DeJesus, Eric M. Yoshida, et al.. (2015). Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2). Hepatology. 64(2). 360–369. 142 indexed citations

Ouwerkerk‐Mahadevan, Sivi, Maria Beumont‐Mauviel, Monika Peeters, et al.. (2015). Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment. Drugs in R&D. 15(3). 261–270. 19 indexed citations

Jacobson, Ira M., Gregory J. Dore, Graham R. Foster, et al.. (2014). Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 384(9941). 403–413. 333 indexed citations breakdown →

Lenz, Oliver, Leen Vijgen, Jan Martin Berke, et al.. (2012). Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). Journal of Hepatology. 58(3). 445–451. 69 indexed citations

Lenz, Oliver, Bart Fevery, Leen Vijgen, et al.. (2011). TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY. Hepatology. 54. 8 indexed citations

Grinsztejn, Beatriz, Giovanni Di Perri, William Towner, et al.. (2010). A Review of the Safety and Tolerability Profile of the Next-Generation NNRTI Etravirine. AIDS Research and Human Retroviruses. 26(7). 725–733. 1 indexed citations

Yéni, Patrick, Anthony Mills, Monika Peeters, et al.. (2010). Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. Current HIV Research. 8(7). 564–576. 2 indexed citations

10.

Kakuda, Thomas N., Janet R. Wade, Eric Snoeck, et al.. (2010). Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients. Clinical Pharmacology & Therapeutics. 88(5). 695–703. 37 indexed citations

11.

Vingerhoets, Johan, Lotke Tambuyzer, Hilde Azijn, et al.. (2010). Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 24(4). 503–514. 137 indexed citations

12.

Katlama, Christine, Richard Haubrich, Jacob Lalezari, et al.. (2009). Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 23(17). 2289–2300. 148 indexed citations

13.

Cohen, Calvin, Daniel S Berger, Gary Blick, et al.. (2009). Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS. 23(3). 423–426. 23 indexed citations

14.

Kakuda, Thomas N., Monika Peeters, Chris Corbett, et al.. (2008). Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2. 46th Annual Meeting. 5 indexed citations

15.

Schöller‐Gyüre, Monika, Wim van den Brink, Thomas N. Kakuda, et al.. (2008). Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV‐Negative Volunteers. The Journal of Clinical Pharmacology. 48(3). 322–329. 33 indexed citations

16.

Schöller‐Gyüre, Monika, Thomas N. Kakuda, Goedele De Smedt, et al.. (2008). A pharmacokinetic study of etravirine (TMC125) co‐administered with ranitidine and omeprazole in HIV–negative volunteers. British Journal of Clinical Pharmacology. 66(4). 508–516. 50 indexed citations

17.

Arastéh, Keikawus, Nathan Clumeck, Anton Pozniak, et al.. (2005). TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS. 19(9). 943–947. 35 indexed citations

18.

Gazzard, Brian, Anton Pozniak, Schlomo Staszewski, et al.. (2003). An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. 17(18). F49–F54. 97 indexed citations

19.

Rakhmanova, Aza, A. A. Yakovlev, Monika Peeters, et al.. (2003). A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS. 17(17). 2487–2494. 68 indexed citations

20.

Miller, Veronica, Thomas Stark, J. De Crée, et al.. (1996). Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS. 10(5). F1–F7. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact